Drug
Dimethyl Fumarate Enteric-coated Capsules
Dimethyl Fumarate Enteric-coated Capsules is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_4
1
33%
Ph phase_3
1
33%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)
Trials by Status
recruiting267%
not_yet_recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_2
Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes
NCT07548996
recruitingphase_3
Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus
NCT07258394
not_yet_recruitingphase_4
A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)
NCT07138833
Clinical Trials (3)
Showing 3 of 3 trials
NCT07548996Phase 2
Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes
NCT07258394Phase 3
Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus
NCT07138833Phase 4
A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3